Alnylam Pharmaceuticals

Each annual produced for Alnylam has been developed around a specific theme related to annual research, partnership, or clinical results.

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. Alnylam is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases.

★★★ NATIONAL DESIGN AWARDS

• Categories: Print
• Projects Completed: Corporate annual reports